Business Wire: AtaCor Medical to Present Preliminary Results from First-in-Human Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study AtaCor Medical to Present Preliminary Results from First-in-Human Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study Business Wire: AtaCor Medical Completes Enrollment in its Initial Acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study. AtaCor Medical Completes Enrollment in its Initial Acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study The benefit of implantable cardioverter-defibrillators (ICDs) on patient outcomes following cardiac arrest has been established in the general population, but the impact of ICDs on mortality in ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. I was 20 years old the first time my implantable cardioverter-defibrillator (ICD) delivered a shock to my heart. It felt ... SAN FRANCISCO — An implantable cardioverter defibrillator (ICD) with a lead system that inserts just below the sternum performed promisingly in a recent early experience that sets the stage for a more ...
